3rd Quarter - Amendment
DENDREON PHARMACEUTICALS, LLC for DENDREON PHARMACEUTICALS, LLC
Income
—
Expenses
$58,750
Expense method
A: Lobbying Disclosure Act definitions
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 3rd Quarter - Report | Sep 21, 2020 | $58,750 | Replaced |
| 3rd Quarter - Amendment (this page) | Sep 21, 2020 | $58,750 | Yes |
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Medical/Disease Research/Clinical Labs MED
Medicare Part B payment reform. S. 2543, the Prescription Drug Pricing Reduction Act of 2019, and H.R. 3, the Lower Drug Costs Now Act of 2019.
Foreign entity interest: Dendreon, a subsidiary of Nanjing Xinjiekou Department Store, Co. Ltd. in China.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANDREW SAELENS | — |
Foreign entities
Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.
| Entity | Country | Principal place of business | Ownership | Contribution declared |
|---|---|---|---|---|
| NANJING XINJIEKOU DEPARTMENT STORE, CO. LTD. | China | China | 100.0% | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.